Document is current
Any future updates will be listed below
-
Authors
Adami, Giovanni
Orsolini, Giovanni
Rossini, Maurizio
Fratucello, Anna
Fassio, Angelo
Viapiana, Ombretta
Fracassi, Elena
Bixio, Riccardo
Gatti, Davide
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 5 March 2024
Accepted: 2 September 2024
First Online: 10 September 2024
Declarations
:
: This study was approved by the University of Verona ethic committee (prot. WI232128), in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was collected for each participant. Clinical trial number: not applicable.
: Not applicable.
: Giovanni Adami has received advisory board honoraria, consultancy fees and/or speaker fees from Theramex, UCB, Lilly, Galapagos, Fresenius Kabi, Amgen, BMS, Abiogen and Pfizer. Davide Gatti has received advisory board honoraria, consultancy fees and/or speaker fees from Abiogen, Celgene, Eli-Lilly, Neopharmed-Gentili, Pfizer, UCB. Maurizio Rossini reports advisory board honoraria, consultancy fees and/or speaker fees from AbbVie, Amgen, BMS, Eli-Lilly, Galapagos, Menarini, Sandoz, Theramex, UCB, outside the submitted work. Ombretta Viapiana has received advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Eli-Lilly, UCB, Abbvie, MSD, BMS. Angelo Fassio reports personal fees from Abiogen, Novartis, Neopharmed. The other authors have disclosed no conflicts of interest.
